This site is intended only for healthcare professionals resident in the United Kingdom

IBRANCE is indicated for the treatment of HR+/HER2-, locally advanced or mBC in combination with an AI or with fulvestrant in women who have received prior ET. In pre-and peri-menopausal women, the ET should be combined with a LHRH agonist.

Adapting breast cancer care during COVID-19 pandemic

Pfizer is committed to supporting its NHS colleagues during the COVID-19 pandemic. NHS England has released guidance on the management of cancer patients at this difficult time.² This guidance provides the following recommendations which we believe we can provide assistance with:

Consider dispensing longer periods of oral medications if at all possible, to minimise patient exposure
Seek alternative methods to monitor and review patients on systemic therapies

As such, we would like to bring to your attention the availability of our 3-month packaging for IBRANCE^®▼ (palbociclib). The 3-month packaging is available in addition to the 1-month packaging and can be ordered via the same process.

The following table provides some further useful information when ordering:

PRODUCT CODE	EAN CODE	PIP
IBRANCE^® CAP 125 mg x 63	5415062343258	410-4501
IBRANCE^® CAP 100 mg x 63	5415062343241	410-4519
IBRANCE^® CAP 75 mg x 63	5415062343227	410-3909

We can confirm that we are not making any changes to the current patient access scheme.

In line with our Summary of Product Characteristics, for patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, complete blood counts for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.¹ These patients may benefit from the 3-month packaging.

Should you require any help or assistance with necessary coding for the 3-month packaging, please contact our Customer Contact Centre on 0845 608 8866. Alternatively, you can contact your local Pfizer representative.

AI, aromatase inhibitor; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LHRH, luteinising hormone-releasing hormone.

References:
1. Pfizer. IBRANCE^® (palbociclib) Summary of Product Characteristics. December 2019. Available at: https://www.medicines.org.uk/emc/medicine/32638 (accessed March 2020)
2. NHS England. Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer. Publications approval reference: 001559. Available at: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf (accessed March 2020).

PP-IBR-GBR-2318. April 2020